interview
Slack Capital interview: Chris Marlett, Chairman of the...
Last week, Slack Capital - an Australian investment research publication - released an investment...
interview
Slack Capital interview: Chris Marlett, Chairman of the...
Last week, Slack Capital - an Australian investment research publication - released an investment...
investors
Slack Capital interview: Damien Perriman, CCO
Last week, Slack Capital - an Australian investment research publication - has released an...
investors
Slack Capital interview: Damien Perriman, CCO (teaser)
Last week, Slack Capital - an Australian investment research publication - has released an...
Webinars
eXoZymes first quarter 2025 and subsidiary NCTx update
eXoZymes Inc. (NASDAQ: EXOZ) [“eXoZymes”] - a pioneer of AI-engineered enzymes that can transform...
investors
Slack Capital interview: Tyler Korman, VP of Research
This week, Slack Capital - an Australian investment research publication - has released an...
interview
Slack Capital interview: Michael Heltzen, CEO
Today, Slack Capital - an Australian investment research publication - has released an investment...
interview
Slack Capital interview: Michael Heltzen, CEO (teaser)
Today, Slack Capital - an Australian investment research publication - has released an investment...
investors
eXoZymes launches subsidiary, NCTx, to unlock a promising...
At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of...
investors
AI transforming biotechnology: From form with AlphaFold...
Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states: "The Large Language...
understanding exozymes
BioClick - an enzyme engineering game-changer
BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme...
Webinars
eXoZymes 4th quarter and full year 2024 results...
eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform...